ALPMF
Astellas Pharma Inc.
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
16.25
▼ 0.20 (1.22%)
MARKET · —
Price
Open
16.25
Prev close
16.45
Day high
14.90
Day low
14.90
Volume
400
Market cap
$29.14B
P/E (TTM)
15.78
52W range
9.85 – 17.85
Trailing performance
Returnvs SPY
1W
+0.62%
+2.0%
1M
+26.46%
+22.7%
3M
+11.76%
+8.7%
6M
-0.98%
-12.0%
YTD
+23.39%
+11.1%
1Y
+41.55%
+21.6%
3Y
+5.79%
-68.4%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$29.14B
Enterprise value$376.07B
Revenue (TTM)$2.27T
Gross profit$1.84T
EBITDA$669.55B
Net income$364.94B
EPS (TTM)$1.03
Free cash flow$383.56B
Total cash$244.70B
Total debt$589.87B
Book value / share$6.82
Shares outstanding1.79B
Float1.79B
Short % of float—
Dividend yield3.10%
Beta (5Y)0.08
Valuation & profitability ratios
Trailing P/E15.78
Forward P/E36.93
PEG ratio—
Price / sales—
Price / book2.38
EV / revenue0.17
EV / EBITDA0.56
Gross margin80.82%
Operating margin28.92%
Profit margin16.05%
Return on equity21.30%
Return on assets8.41%
Debt / equity30.34
Current ratio1.20
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Total revenue | $2.14T | $789.62B | $688.43B | $613.57B |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | $291.54B | $319.72B | $292.16B | $98.71B |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Net income | $291.54B | $319.72B | $292.16B | $98.71B |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $579.34B | +10.5% |
| Next quarter | — | — | $616.94B | +8.0% |
| Current year | — | — | $2.32T | +160.7% |
| Next year | — | — | $2.14T | -7.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders0.11%
Held by institutions62.06%
Institutions holding441
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
2.03M
Total on file
Moving averages & technicals
SMA 10
15.55
+4.50% from price
SMA 20
14.93
+8.83% from price
SMA 50
14.13
+15.02% from price
SMA 100
14.63
+11.10% from price
SMA 200
14.30
+13.64% from price
EMA 12
15.38
+5.66% from price
EMA 26
14.82
+9.63% from price
EMA 50
14.53
+11.85% from price
RSI (14)
56.6
Neutral
MACD (12,26,9)
0.56
Hist 0.15
ATR (14)
1.01
6.21% of price
Realised vol 30D
124.7%
Annualised
Bollinger upper
17.24
20, 2σ
Bollinger lower
12.62
20, 2σ
50 / 200 cross
Death
14.13 vs 14.30
Trend bias
Above 200
+13.64%
Risk profile
Beta vs SPY
-0.40
Less volatile than market
Correlation to SPY
-0.06
Largely independent
Realised vol 30D
124.7%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.0%
Peak to trough
Max drawdown 5Y
-50.6%
Peak to trough
ATR 14
1.01
6.21% of price
Beta (reported)
0.08
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
New Strong Sell Stocks for August 19th
Zacks · 4d ago
Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
PR Newswire · 5d ago
New Strong Sell Stocks for August 6th
Zacks · 17d ago
Pfizer (PFE) Announces FDA Approval of PADCEV plus Keytruda in MIBC
Insider Monkey · 38d ago
Pfizer Poised for Mixed Second Quarter, RBC Says
MT Newswires · 43d ago
U.S. FDA Approves PADCEV® plus Keytruda® as Neoadjuvant and Adjuvant Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
Business Wire · 43d ago
Sangamo holds a bankruptcy sale; VCs back a China-linked Beam competitor
BioPharma Dive · 60d ago
Sector Update: Healthcare Stocks Advance in Afternoon Trading
MT Newswires · 60d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.